Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover study of indacaterol versus placebo and tiotropium in moderate to severe COPD
2007-004071-19Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Novartis. Primary endpoint: 24-hour post-dose trough FEV1 after 14 days of treatment. Started Nov 2007; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-004071-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004071-19.